Oncotarget

Research Papers:

Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase

Jing-Yuan Xu, Long-Bao Yang, Zhi-Yi Han, Kai Wang, Zhen-Hua Yin, Ting Wu, Yong Shao _ and Xiao-Lan Lu _

PDF  |  Full Text  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2021; 12:1398-1405. https://doi.org/10.18632/oncotarget.28009

Metrics: PDF 136 views  |   Full Text 454 views  |   ?  


Abstract

Jing-Yuan Xu1,2,*, Long-Bao Yang1,*, Zhi-Yi Han3, Kai Wang2, Zhen-Hua Yin2, Ting Wu4, Yong Shao4 and Xiao-Lan Lu1,2

1 Department of Gastroenterology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

2 Department of Gastroenterology, Shanghai Pudong Hospital of Fudan University, Shanghai 201399, China

3 Karamay Central Hospital of Xinjiang, Karamay 834099, China

4 Community Health Service Center of Jinxi Town, Kunshan 215300, China

* These authors contributed equally to this work

Correspondence to:

Xiao-Lan Lu,email: xiaolan_lu@163.com
Yong Shao,email: sy.580@163.com

Keywords: type 2 diabetes; alanine aminotransferase; aspartate aminotransferase; body mass index

Received: January 01, 2021     Accepted: June 11, 2021     Published: July 06, 2021

Copyright: © 2021 Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background/Purpose: Recent study suggested that type 2 diabetes (T2DM) attributed to body mass index (BMI) could be influenced by liver aminotransferase. We aim to ascertain the cut-off point of BMI associated with T2DM and the influence of both elevated aminotransferase (AST) and alanine aminotransferase (ALT).

Materials and Methods: In our retrospective cohort study, T2DM was diagnosed when FBS ≥ 7.0 mmol/L, BMI of participants with baseline fasting (FBS) < 7.0 mmol/L was divided by percentiles and by aminotransferanse (ALT and AST ≥ 20 U/L, ALT or AST < 20 U/L). Hazard ratios and the turning point of BMI of high T2DM risk was estimated in totality and different aminotransferanse groups.

Results: During an average follow-up time of 3.71 years of 33346 participants, 1486 developed T2DM, and the average baseline BMI of participants who developed T2DM was 26.22 kg/m2. Cumulative incidence of T2DM was more than 5% when ALT and AST ≥ 20U/L, age over 44, male sex or BMI over 25.39 kg/m2; The risk of T2DM incidence increased as the BMI grow. The turning point of BMI at high risk of T2DM was 25.0 kg/m2 in totality, 25.1 kg/m2 when ALT or AST < 20 U/L and 26.1 kg/m2 when ALT and AST ≥ 20U/L.

Conclusions: BMI of 25.0 kg/m2 was the cutoff point for T2DM development, and there is greater association between BMI and T2DM when ALT or AST < 20 U/L.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28009